Key clinical point: Transarterial chemoembolization (TACE) demonstrated a comparable safety profile between elderly and younger patients with intermediate hepatocellular carcinoma (HCC), with its efficacy remaining uncompromised with advancing age.
Major finding: The occurrence rate of at least one serious adverse event was similar between elderly and younger patients (20.5% vs. 21.3%; P = .87). The objective tumor response rate did not decline in the elderly patients (89.5%) compared with that in younger patients (78.7%).
Study details: The data come from a retrospective study including 271 patients aged >18 years with intermediate HCC who underwent the first session of TACE, of which 88 were elderly patients ( ≥70 years old).
Disclosures: The study received no financial support. The authors declared no conflicts of interest.
Source: Roth GS et al. Safety and efficacy of transarterial chemoembolization in elderly patients with intermediate hepatocellular carcinoma. Cancers. 2022;14(7):1634 (Mar 23). Doi: 10.3390/cancers14071634
